Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We aimed to identify gene expression signatures associated with angiogenesis and hypoxia pathways with predictive value for treatment response to bevacizumab/erlotinib (BE) of nonsquamous advanced non-small cell lung cancer (NSCLC) patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Cancer Res.

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

Publisher: American Association for Cancer Research (AACR)

ISSN: 1078-0432

ISSN (Print): 1078-0432

Publication date (Electronic): Dec 01 2015

Volume: 21

Issue: 23

Affiliations

[1 ] Department of Pulmonary Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

[2 ] Department of Pulmonary Diseases, University of Medicine and Pharmacy, Iasi, Romania.

[3 ] Institute of Data Analysis and Process Design, Zürich University of Applied Sciences, Winterthur, Switzerland.

[4 ] Männedorf Hospital, Männedorf, Switzerland.

[5 ] Cantonal Hospital Fribourg, Fribourg, Switzerland.

[6 ] Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.

[7 ] Department of Medical Oncology, Clinica Luganese, Lugano, Switzerland.

[8 ] Department of Pulmonary Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. martin.brutsche@kssg.ch.

Article

Publisher Item ID: 1078-0432.CCR-14-3135

DOI: 10.1158/1078-0432.CCR-14-3135

PubMed ID: 25922429

SO-VID: cde64125-f0ee-494f-8125-7e7f2be73068

History

Data availability:

Comments

Comment on this article

scite_

Cited by 3

See all cited by